Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 9.15% is 280% above its 2-year average of -5.08%, near the high end of its 2-year range (-29.06%–19.21%).
18.93% below its 12-month average of 11.29%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 8.13%.
EBITDA MARGIN
9.15%
EBITDA MARGIN AVG TTM
11.29%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-18.93%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$4.92B
EBITDA Margin
-8718.32%
TTM Avg
-5172.73%
3Y Avg
-3124.55%
5Y Avg
-2649.58%
Market Cap
$5.20B
EBITDA Margin
-395.82%
TTM Avg
-536.17%
3Y Avg
-471.62%
5Y Avg
-471.62%
Market Cap
$5.20B
EBITDA Margin
21.06%
TTM Avg
20.50%
3Y Avg
18.63%
5Y Avg
16.67%
Market Cap
$4.78B
EBITDA Margin
-14.19%
TTM Avg
-47.13%
3Y Avg
-77.82%
5Y Avg
-97.39%
Market Cap
$5.27B
EBITDA Margin
-1035.18%
TTM Avg
-586.23%
3Y Avg
-456.90%
5Y Avg
-388.23%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BillionToOne, Inc. (BLLN) | $5.02B | 9.15% | 11.29% | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.92B | -8718.32% | -5172.73% | -3124.55% | -2649.58% |
| Erasca, Inc. (ERAS)vs › | $5.11B | N/A | N/A | N/A | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.20B | -395.82% | -536.17% | -471.62% | -471.62% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.20B | 21.06% | 20.50% | 18.63% | 16.67% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.78B | -14.19% | -47.13% | -77.82% | -97.39% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.27B | -1035.18% | -586.23% | -456.90% | -388.23% |
| Doximity, Inc. (DOCS)vs › | $5.35B | 35.56% | 38.69% | 36.58% | 34.55% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.50B | -31.52% | -36.86% | -49.55% | -49.55% |
Gross Margin
71.3%
EBITDA Margin
9.2%
Operating Margin
10.9%
Net Margin
8.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 8.13% |
| 2026-03-31 | 19.21% |
| 2025-12-31 | 13.84% |
| 2025-09-30 | 15.07% |
| 2025-06-30 | 0.18% |
| 2025-03-31 | -0.89% |
| 2024-12-31 | -21.95% |
| 2024-09-30 | -28.18% |
| 2024-06-30 | -27.16% |
| 2024-03-31 | -29.06% |
